Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative

O Sipos1, H Tovey2, J Quist3

  • 1Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.

Abstract

Insights

Patients with triple-negative breast cancer lacking high-level amplifications (HLAMP) and showing intermediate chromosomal instability (CIN) benefit more from carboplatin than docetaxel. This finding identifies a subgroup with improved outcomes in the TNT trial.

Area of Science:

  • Oncology
  • Genomics
  • Cancer Research

Background:

  • Germline BRCA1/2 mutations are found in 28% of carboplatin responders in triple-negative breast cancer (TNT trial).
  • Structural chromosomal instability (CIN) was assessed to identify a broader patient subgroup benefiting from carboplatin over docetaxel.

Purpose of the Study:

  • To identify a wider patient subgroup within the TNT trial who preferentially benefit from carboplatin over docetaxel.
  • To assess quantitative measures of structural chromosomal instability (CIN) for treatment selection in triple-negative breast cancer.

Main Methods:

  • Copy number aberrations (CNAs) were analyzed from 135 primary carcinomas using SNP-arrays.
  • Nine CIN measurements, including novel high-level amplifications (HLAMP) and Shannon diversity index (SI), were derived and analyzed.
  • CIN measurements were categorized into tertiles to correlate with objective response rate (ORR) and progression-free survival (PFS).

Main Results:

  • Tumors without HLAMP showed higher ORR and significantly longer PFS with carboplatin versus docetaxel (PFS: 6.1 vs. 4.1 months).
  • Intermediate levels of allelic imbalanced CNA (AiCNA) and telomeric allelic imbalances (NtAI) correlated with higher ORR in the carboplatin arm.
  • High AiCNA and percentage of genome altered (PGA) were associated with shorter PFS in the carboplatin arm, but not the docetaxel arm.

Conclusions:

  • Patients with tumors lacking HLAMP and intermediate CIN measurements represent a subgroup benefiting from carboplatin over docetaxel in the TNT trial.
  • Genomic instability in primary tumors exhibits a complex relationship with treatment response in metastatic triple-negative breast cancer.

Related Concept Videos